Literature DB >> 22246845

Rubella immune status among immigrant and nonimmigrant women in Spain.

J M Ramos1, A Milla, J C Rodríguez, F Gutiérrez.   

Abstract

A cross-sectional study of seroprevalence of rubella antibodies was carried out in all immigrant pregnant women (1,627) from February 2006 to June 2010. For each immigrant woman one Spanish pregnant woman was recruited. The seroprevalence of IgG antibodies against rubella in immigrant women was 92% (95% confidence interval [CI]: 90.4-93.3), and in native women was 97.7% (95%CI: 96.7-98.4) (P < 0.001). Immunity against was lowest among women from Latin America (odds ratio [OR]: 0.17), followed by women from Asia (OR: 0.20), Sub-Saharan Africa (OR: 0.27) and Northern Africa (OR: 0.37). Female immigrants from developing countries should be targeted for immunization to reduce the risk of congenital rubella.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22246845     DOI: 10.1002/jmv.23195

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  4 in total

1.  Rubella Immunity in Pregnant Native Taiwanese and Immigrants from Asian Countries.

Authors:  Yeong-Hwa Zen; Ching-Tang Shih; Wan-Ju Kung; Chien-Hung Lee; Ching-Chiang Lin
Journal:  Am J Trop Med Hyg       Date:  2016-11-28       Impact factor: 2.345

2.  Seroprevalence of rubella in northeastern Turkey.

Authors:  Yasemin Akkoyunlu; Gulhan Arvas; Tamer Ozsarı; Ismail Necati Hakyemez; Bulent Kaya; Turan Aslan
Journal:  Wien Klin Wochenschr       Date:  2013-06-21       Impact factor: 2.275

Review 3.  Hispano-Americans in Europe: what do we know about their health status and determinants? A scoping review.

Authors:  Maria Roura; Andreu Domingo; Juan M Leyva-Moral; Robert Pool
Journal:  BMC Public Health       Date:  2015-05-07       Impact factor: 3.295

4.  Rubella immunity in women of childbearing age, eight years after the immunization program in iran.

Authors:  Rahim Barari Sawadkohi; Amin Zarghami; Fatemeh Izadpana; Mohammad Pournasrollah
Journal:  Iran Red Crescent Med J       Date:  2014-07-05       Impact factor: 0.611

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.